Michel T. Corban
- Assistant Professor, Medicine - (Clinical Scholar Track)
- (520) 626-8927
- AHSC, Rm. 2301
- mtcorban@arizona.edu
Biography
Michel T. Corban, MD, is a board-certified interventional cardiologist and clinical researcher with expertise in percutaneous coronary interventions, coronary physiology, and structural heart disease interventions. He is also an Assistant Professor of Medicine at the University of Arizona Sarver Heart Center.
Dr. Corban received his MD degree from the American University of Beirut in Lebanon. He then completed a postdoctoral research fellowship in interventional cardiology and his internal medicine residency training at Emory University in Atlanta, GA, followed by a cardiovascular disease fellowship, an interventional cardiology fellowship, and an advanced fellowship in structural heart disease interventions at the Mayo Clinic in Rochester, MN.
Clinical Practice:
Dr. Corban's clinical practice focuses on the treatment of patients with coronary artery disease requiring percutaneous coronary interventions, invasive diagnosis and treatment of patients with coronary microvascular dysfunction (diseases of the smallest heart vessels) and endothelial dysfunction (diseases of the inner cell lining of the heart vessels), and performing transcatheter interventions for patients with valvular heart disease (such as severe aortic valve stenosis for which he has done more than 250 transcatheter aortic valve replacement [TAVR] procedures) and non-valvular structural heart diseases (such as device closure of patent foramen ovale and atrial septal defect, and alcohol septal ablations for hypertrophic obstructive cardiomyopathy).
Dr. Corban has an active research program and is nationally recognized in coronary physiology, coronary microvascular dysfunction, and coronary endothelial dysfunction research. He is also a clinical trialist investigating cell therapy and novel implantable device therapies for coronary microvascular and endothelial dysfunction. In addition, his research interests also include sex-specific differences in coronary physiology, myocardial bridging, and intravascular imaging for atherosclerotic plaque development, progression, and vulnerability.
Degrees
- M.D. Medicine
- American University of Beirut, Beirut, Lebanon
- B.S. Biology
- American University of Beirut, Beirut, Lebanon
Work Experience
- University of Arizona, Tucson, Arizona (2021 - Ongoing)
- Banner University Medical Center (2021 - Ongoing)
Licensure & Certification
- ABIM Internal Medicine, ABIM (2016)
- NBE Comprehensive (TTE, TEE, Stress Echo) Echocardiography, NBE (2018)
- ABIM Cardiovascular Disease, ABIM (2019)
- ABIM Interventional Cardiology, ABIM (2020)
- Arizona State Medical License (2021)
Interests
No activities entered.
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Corban, M. T., Toya, T., Albers, D., Sebaali, F., Lewis, B. R., Bois, J., Gulati, R., Prasad, A., Best, P. J., Bell, M. R., Rihal, C. S., Prasad, M., Ahmad, A., Lerman, L. O., Solseth, M. L., Winters, J. L., Dietz, A. B., & Lerman, A. (2022). IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries. Circulation research, 130(3), 326-338.More infoCoronary endothelial dysfunction (CED) causes angina/ischemia in patients with nonobstructive coronary artery disease (NOCAD). Patients with CED have decreased number and function of CD34+ cells involved in normal vascular repair with microcirculatory regenerative potential and paracrine anti-inflammatory effects. We evaluated safety and potential efficacy of intracoronary autologous CD34+ cell therapy for CED.
- Henry, T. D., Bairey Merz, C. N., Wei, J., Corban, M. T., Quesada, O., Joung, S., Kotynski, C. L., Wang, J., Lewis, M., Schumacher, A. M., Bartel, R. L., Takagi, H., Shah, V., Lee, A., Sietsema, W. K., Losordo, D. W., & Lerman, A. (2022). Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction. Circulation. Cardiovascular interventions, 15(2), e010802.More infoCoronary microvascular dysfunction results in angina and adverse outcomes in patients with evidence of ischemia and nonobstructive coronary artery disease; however, no specific therapy exists. CD34+ cell therapy increases microvasculature in preclinical models and improves symptoms, exercise tolerance, and mortality in refractory angina patients with obstructive coronary artery disease. The objective of this research was to evaluate the safety, tolerability, and efficacy of intracoronary CD34+ cell therapy in patients with coronary microvascular dysfunction.
- Ozcan, I., Toya, T., Corban, M. T., Ahmad, A., Loeffler, D., Morse, D., Lerman, L. O., Kushwaha, S. S., & Lerman, A. (2022). Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients. Cardiovascular research, 118(7), 1703-1712.More infoCirculating progenitor cells (CPCs) play a role in vascular repair and plaque stability, while osteocalcin (OC) expressing CPCs have been linked to unstable plaque and adverse cardiovascular outcomes. However, their role in cardiac allograft vasculopathy (CAV) has not been elucidated. This cohort study aimed to investigate the contribution of CPCs on CAV progression and cardiovascular events after heart transplantation.
- Park, H. W., Corban, M., Toya, T., Ahmad, A., Ozcan, I., Lerman, L., & Lerman, A. (2022). Impact of invasive aortic pulse pressure on coronary microvascular endothelial-independent dysfunction and on mortality in non-obstructive coronary artery disease. Open heart, 9(1).More infoPulse pressure (PP), a raw index of arterial stiffness, is inversely related to coronary microvascular function, even among patients with non-obstructive coronary artery disease (CAD), as per non-invasive studies. We aimed to determine whether invasive aortic PP is associated with coronary microvascular endothelial dysfunction (CMED) and/or coronary microvascular endothelial independent dysfunction (CMEID) in patients with non-obstructed CAD.
- Ahmad, A., Corban, M. T., & Lerman, A. (2021). Contrast fractional flow reserve vs adenosine fractional flow reserve: The impact of discordant results. International journal of cardiology, 328, 59-60.
- Ahmad, A., Corban, M. T., Toya, T., Attia, Z. I., Noseworthy, P. A., Lopez-Jimenez, F., Cohen, M. S., Sara, J. D., Ozcan, I., Lerman, L. O., Kapa, S., Friedman, P. A., & Lerman, A. (2021). Coronary Microvascular Dysfunction and the Risk of Atrial Fibrillation From an Artificial Intelligence-Enabled Electrocardiogram. Circulation. Arrhythmia and electrophysiology, 14(8), e009947.
- Ahmad, A., Corban, M. T., Toya, T., Verbrugge, F. H., Sara, J. D., Lerman, L. O., Borlaug, B. A., & Lerman, A. (2021). Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. European journal of heart failure, 23(5), 765-772.More infoThis study uniquely explored the relationship between coronary microvascular function and exercise haemodynamics using concurrent invasive testing.
- Ahmad, A., Shelly-Cohen, M., Corban, M. T., Murphree, D. H., Toya, T., Sara, J. D., Ozcan, I., Lerman, L. O., Friedman, P. A., Attia, Z. I., & Lerman, A. (2021). Machine learning aids clinical decision-making in patients presenting with angina and non-obstructive coronary artery disease. European heart journal. Digital health, 2(4), 597-605.More infoThe current gold standard comprehensive assessment of coronary microvascular dysfunction (CMD) is through a limited-access invasive catheterization lab procedure. We aimed to develop a point-of-care tool to assist clinical guidance in patients presenting with chest pain and/or an abnormal cardiac functional stress test and with non-obstructive coronary artery disease (NOCAD).
- Corban, M. T., Prasad, A., Gulati, R., Lerman, L. O., & Lerman, A. (2021). Sex-specific differences in coronary blood flow and flow velocity reserve in symptomatic patients with non-obstructive disease. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 16(13), 1079-1084.More infoReduced coronary flow velocity reserve (CFVR) is associated with adverse cardiovascular outcomes. Whether CFVR and coronary blood flow (CBF) are similar in men and women with chest pain and non-obstructive CAD remains unknown. We hypothesised sex differences in CFVR and CBF.
- Corban, M. T., Toya, T., Ahmad, A., Lerman, L. O., Lee, H. C., & Lerman, A. (2021). Atrial Fibrillation and Endothelial Dysfunction: A Potential Link?. Mayo Clinic proceedings, 96(6), 1609-1621.More infoAtrial fibrillation (AF) is the most common cardiac arrhythmia, and coronary atherosclerosis is the leading cause of death in the United States and worldwide. Endothelial dysfunction is the earliest clinically detectable form of atherosclerosis. Control of shared AF and coronary atherosclerosis risk factors improves both AF-free survival and vascular endothelial function. Decades of AF research have yielded fundamental insight into AF pathophysiology, but current pharmacological and catheter-based invasive AF therapies have limited long-term efficacy and substantial side effects, possibly because of incomplete understanding of underlying complex AF pathophysiology. We hereby discuss potential mechanistic links between endothelial dysfunction and AF (risk-factor-associated systemic inflammation and oxidative stress, myocardial ischemia, common gene variants, vascular shear stress, and fibroblast growth factor-23), explore a potential new vascular dimension to AF pathophysiology, highlight a growing body of evidence supporting an association between systemic vascular endothelial dysfunction, AF, and stroke, and discuss potential common effective therapies.
- Liu, H., Xie, G., Huang, W., Liu, J., Zhao, N., Corban, M. T., Lerman, A., Wu, Y., & Wang, H. (2021). Rationale and design of a multicenter, randomized, patients-blinded two-stage clinical trial on effects of endothelial function test in patients with non-obstructive coronary artery disease (ENDOFIND). International journal of cardiology, 325, 16-22.More infoAbnormal peripheral and coronary endothelial function has been associated with increased risk of major adverse cardiovascular events (MACE) in cross-sectional retrospective and observational studies. However, prognostic value of routine clinical evaluation, diagnosis and treatment of endothelial dysfunction on incident MACE in patients with non-obstructive coronary artery disease (NOCAD) remains unknown. Endothelial Function Guided Management in Patients with NOCAD (ENDOFIND) is a multicenter, randomized, patients-blinded, parallel-controlled, two-stage clinical trial evaluating the impact of routine clinical peripheral endothelial function testing on initiation and/or intensification of cardiovascular preventive therapies in Stage I, and on the risk of MACE in Stage II in patients with NOCAD. One thousand participants with NOCAD on clinically indicated coronary computed tomography or invasive angiography will be enrolled and randomized 1:1, after baseline peripheral endothelial function evaluation, to either endothelial function guided treatment group or standard of care control group. In Stage I, patients will be followed for 12 months and primary outcome will be the proportion of patients receiving prescriptions for cardiovascular evidence-based lipid, blood pressure and glucose lowering medications at the clinic visit immediately after endothelial function evaluation. Secondary outcomes are change in endothelial function measured as reactive hyperemia index and patients' adherence to evidence-based medications in 12 months. Study will be extended into Stage II where sample size and follow up duration will be reevaluated to ensure statistical power, and primary outcome will be incident MACE. ENDOFIND is proof-of-concept clinical trial of a disruptive endothelial function guided clinical intervention with potential benefits to NOCAD patients. CONDENSED ABSTRACT: ENDOFIND is a proof-of-concept clinical trial of a disruptive endothelial function guided clinical intervention with potential benefits to patients with no obstructive coronary artery disease (NOCAD). It is a multicenter, randomized, patients-blinded, parallel controlled two-stage clinical trial to evaluate the impact of routine clinical peripheral endothelial function testing on initiation and/or intensification of cardiovascular disease preventive therapies in Stage I, and on the risk of MACE in Stage II.
- Mahowald, M. K., Corban, M. T., Eleid, M. F., & Nishimura, R. A. (2021). Alcohol Septal Ablation for Hypertrophic Cardiomyopathy Through an Anomalous Septal Perforator Off the Right Cusp. JACC. Cardiovascular interventions, 14(12), e129-e130.
- Ozcan, I., Toya, T., Corban, M. T., Ahmad, A., Lerman, L. O., Kushwaha, S. S., & Lerman, A. (2021). Peripheral microvascular dysfunction is associated with plaque progression and adverse long-term outcomes in heart transplant patients. ESC heart failure, 8(6), 5266-5274.More infoCardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non-heart transplant population. We aimed to investigate the association of PED with future MACE, and plaque progression assessed by intravascular ultrasound (IVUS) after heart transplantation.
- Toya, T., Ahmad, A., Corban, M. T., Ӧzcan, I., Sara, J. D., Sebaali, F., Escaned, J., Lerman, L. O., & Lerman, A. (2021). Risk Stratification of Patients With NonObstructive Coronary Artery Disease Using Resistive Reserve Ratio. Journal of the American Heart Association, 10(11), e020464.More infoBackground Resistive reserve ratio (RRR), or the ratio of baseline to hyperemic microvascular resistance, has prognostic implications in predicting clinical outcomes in patients with obstructive coronary artery disease. However, its value in patients with angina or ischemia with nonobstructive coronary artery disease is unknown. Methods and Results We included 1692 patients with nonobstructive coronary artery disease who underwent invasive coronary vasoreactivity testing. Abnormal coronary flow reserve (CFR, the ratio of hyperemic and baseline resting flow velocities) and RRR were defined as
- Toya, T., Corban, M. T., Park, J. Y., Ahmad, A., Ӧzcan, I., Sebaali, F., Sara, J. D., Gulati, R., Lerman, L. O., & Lerman, A. (2021). Prognostic impact and clinical outcomes of coronary flow reserve and hyperaemic microvascular resistance. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 17(7), 569-575.More infoMost studies dichotomise indices of coronary microvascular function to assess their prognostic values.
- Toya, T., Ozcan, I., Corban, M. T., Sara, J. D., Marietta, E. V., Ahmad, A., Horwath, I. E., Loeffler, D. L., Murray, J. A., Lerman, L. O., & Lerman, A. (2021). Compositional change of gut microbiome and osteocalcin expressing endothelial progenitor cells in patients with coronary artery disease. PloS one, 16(3), e0249187.More infoOsteogenic endothelial progenitor cells (EPCs) contribute to impaired endothelial repair and promote coronary artery disease (CAD) and vascular calcification. Immature EPCs expressing osteocalcin (OCN) has been linked to unstable CAD; however, phenotypic regulation of OCN-expressing EPCs is not understood. We hypothesized that gut-microbiome derived pro-inflammatory substance, trimethylamine N-oxide (TMAO) might be associated with mobilization of OCN-expressing EPCs. This study aimed to investigate the association between dysbiosis, TMAO, and circulating mature and immature OCN-expressing EPCs levels in patients with and without CAD. We included 202 patients (CAD N = 88; no CAD N = 114) who underwent assessment of EPCs using flow cytometry and gut microbiome composition. Mature and immature EPCs co-staining for OCN were identified using cell surface markers as CD34+/CD133-/kinase insert domain receptor (KDR)+ and CD34-/CD133+/KDR+ cells, respectively. The number of observed operational taxonomy units (OTU), index of microbial richness, was used to identify patients with dysbiosis. The number of immature OCN-expressing EPCs were higher in patients with CAD or dysbiosis than patients without. TMAO levels were not associated with circulating levels of OCN-expressing EPCs. The relative abundance of Ruminococcus gnavus was moderately correlated with circulating levels of immature OCN-expressing EPCs, especially in diabetic patients. Gut dysbiosis was associated with increased levels of TMAO, immature OCN-expressing EPCs, and CAD. The relative abundance of Ruminococcus gnavus was correlated with immature OCN-expressing EPCs, suggesting that the harmful effects of immature OCN-expressing EPCs on CAD and potentially vascular calcification might be mediated by gut microbiome-derived systemic inflammation.
- Ahmad, A., Corban, M. T., Toya, T., Sara, J. D., Lerman, B., Park, J. Y., Lerman, L. O., & Lerman, A. (2020). Coronary Microvascular Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Artery Disease Is Associated With Elevated Serum Homocysteine Levels. Journal of the American Heart Association, 9(19), e017746.More infoBackground Elevated levels of serum homocysteine, via impaired nitric oxide production, and coronary microvascular dysfunction are associated with increased risk of major adverse cardiovascular events. However, whether serum homocysteine levels and coronary microvascular endothelial dysfunction (CMED) are linked remains unknown. Methods and Results This study included 1418 patients with chest pain or an abnormal functional stress test and with nonobstructive coronary artery disease (
- Corban, M. T., Godo, S., Burczak, D. R., Noseworthy, P. A., Toya, T., Lewis, B. R., Lerman, L. O., Gulati, R., & Lerman, A. (2020). Coronary Endothelial Dysfunction Is Associated With Increased Risk of Incident Atrial Fibrillation. Journal of the American Heart Association, 9(8), e014850.More infoBackground Coronary artery disease risk factors are associated with atrial fibrillation (AF) and coronary endothelial dysfunction (CED). We hypothesized that CED is associated with increased risk of incident AF among patients with chest pain and nonobstructive coronary artery disease. Methods and Results Three hundred patients with chest pain, nonobstructive coronary artery disease, and no history of AF underwent intracoronary acetylcholine infusion for evaluation of baseline epicardial (decrease in mid-left anterior descending coronary artery diameter in response to acetylcholine) and microvascular (34 mL/m) left atrial volume index (odds ratio, 3.87; 95% CI, 1.60-9.11) were independent predictors of incident AF. Conclusions Patients with normal coronary endothelial function, as compared with those with CED and similar AF risk factors, have significantly lower incidence of AF on long-term follow-up. The potential mechanistic link between vascular dysfunction and AF development warrants further investigation.
- Corban, M. T., Lerman, L. O., & Lerman, A. (2020). Endothelin-1 in coronary microvascular dysfunction: a potential new therapeutic target once again. European heart journal, 41(34), 3252-3254.
- Corban, M. T., Widmer, R. J., Cilluffo, R., Kazeck, M. A., Lennon, R. J., Lerman, L. O., & Lerman, A. (2020). The effect of polyphenol-rich chardonnay seed supplements on peripheral endothelial function. European journal of nutrition, 59(8), 3723-3734.More infoPeripheral endothelial dysfunction (PED) is associated with major adverse cardiovascular events. Similar to cardio-protective Mediterranean diet, Chardonnay seeds are rich in polyphenols, fibers, and grape seed oil. In this randomized double-blinded trial, we investigated safety and incremental benefit of Chardonnay seed polyphenols-rich (PR), compared to polyphenols-free (PF), supplements on PED.
- El-Am, E. A., Corban, M. T., Pollak, A. W., Lerman, A., & Ammash, N. M. (2020). A Challenging Combination: Anomalous Left Anterior Descending Coronary Artery, Myocardial Bridging, and Endothelial Dysfunction. Frontiers in cardiovascular medicine, 7, 57.More info50 years old female patient with a medical history of hypertension presented to the clinic with chest pain, palpitations, and dyspnea on exertion of 2 years duration. Extensive workup in search of the culprit etiology of her chest pain revealed a challenging combination of an anomalous left anterior descending artery with myocardial bridging and endothelial dysfunction. She was treated medically with long acting nitrates, L-arginine and calcium channel blockers, and remains asymptomatic after 12 months of follow up.
- Hebbel, R. P., Wei, P., Milbauer, L., Corban, M. T., Solovey, A., Kiley, J., Pattee, J., Lerman, L. O., Pan, W., & Lerman, A. (2020). Abnormal Endothelial Gene Expression Associated With Early Coronary Atherosclerosis. Journal of the American Heart Association, 9(14), e016134.More infoBackground We examined feasibility of a unique approach towards gaining insight into heritable risk for early atherosclerosis: surveying gene expression by endothelial cells from living subjects. Methods and Results Subjects aged
- Toya, T., Corban, M. T., Imamura, K., Bois, J. P., Gulati, R., Oh, J. K., Lerman, L. O., & Lerman, A. (2020). Coronary perivascular epicardial adipose tissue and major adverse cardiovascular events after ST segment-elevation myocardial infarction. Atherosclerosis, 302, 27-35.More infoPerivascular epicardial adipose tissue (pEAT) plays a key role in the progression of atherosclerosis, plaque rupture, and thrombosis. However, the relationship between pEAT and prognosis after revascularization of ST-segment elevation myocardial infarction (STEMI) is unknown. This study aimed to investigate the relationship between pEAT thickness and prognosis after STEMI.
- Toya, T., Sara, J. D., Lerman, B., Ahmad, A., Taher, R., Godo, S., Corban, M. T., Lerman, L. O., & Lerman, A. (2020). Elevated plasma homocysteine levels are associated with impaired peripheral microvascular vasomotor response. International journal of cardiology. Heart & vasculature, 28, 100515.More infoHyperhomocysteinemia (HHcy) has been proposed as an important cardiovascular risk factor (cRF). However, little is known about the association between plasma homocysteine levels and peripheral microvascular endothelial dysfunction (PMED), which is an integrated index of vascular health.
Presentations
- Corban, M. (2023, August). Cath Practicum. Fellows Conference. Tucson, AZ: Sarver Heart Center, University of Arizona.
- Corban, M. (2023, February). Angio practicum. Fellows Conference. Tucson, AZ: Sarver Heart Center, University of Arizona.
- Corban, M. (2023, March). Angio Practicum. Fellows Conference. Tucson, AZ: Sarver Heart Center, University of Arizona.
- Corban, M. (2023, October). Coronary Physiology Part 1. Fellows Conference. Tucson, AZ: Sarver Heart Center, University of Arizona.
- Corban, M. (2023, September). Cath Practicum. Fellows Conference. Tucson, AZ: Sarver Heart Center, University of Arizona.
Poster Presentations
- Ajmal, M., Kubba, S., Lee, K. S., Lerman, A., & Corban, M. (2022, November). Abstract 11774: Heart Failure with Preserved Ejection Fraction Secondary to Coronary Endothelial Dysfunction and Microvascular Disease. American Heart Association Scientific Sessions 2022. Chicago, IL.
- Muhammad, A., Kolimas, A., Moynahan, K. F., Corban, M., Avila, D., Kotagiri, R., Kazui, T., Kazui, T., Kotagiri, R., Avila, D., Corban, M., Moynahan, K. F., Kolimas, A., & Muhammad, A. (2022, November). Infective endocarditis of the mitral valve in an immunocompetent patient caused by lactobacillus species. American Heart Association Scientific Sessions 2022. Chicago: AHA.
- Seckeler, M., Klewer, S. E., Corban, M., Ibrahim, R., & Takamatsu, C. (2022, November). Transcatheter reconstruction of right ventricular outflow tract after severe external compression by a pseudoaneurysm in an adult with tetralogy of Fallot. American Heart Association 2022 Scientific Sessions. Chicago, IL.